{"DataElement":{"publicId":"2940321","version":"1","preferredName":"Breast Clinical Study Protocol National Comprehensive Cancer Network Therapy Type","preferredDefinition":"the type of National Comprehensive Cancer Network (NCCN) treatment regimen received for breast cancer.","longName":"BRST_CTP_NCCN_TX_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2940306","version":"1","preferredName":"Breast Clinical Study Protocol National Comprehensive Cancer Network Therapy","preferredDefinition":"information relating to breast clinical study protocol treatment and the National Comprehensive Cancer Network (NCCN; an alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care).","longName":"BRST_CTP_NCCN_TX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206725","version":"1","preferredName":"Breast Protocol","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C12971:C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0202-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2940304","version":"1","preferredName":"National Comprehensive Cancer Network Therapy","preferredDefinition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C39471:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network","conceptCode":"C39471","definition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A10067-D7B2-8896-E040-BB89AD4326DD","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A10067-D7C3-8896-E040-BB89AD4326DD","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2940313","version":"1","preferredName":"Breast National Comprehensive Cancer Network Therapy Type","preferredDefinition":"the type of National Comprehensive Cancer Network (NCCN) treatment regimen received for breast cancer.","longName":"BRST_NCCN_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"140","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other NCCN approved regimen","valueDescription":"Other NCCN approved regimen","ValueMeaning":{"publicId":"2940314","version":"1","preferredName":"Other NCCN approved regimen","longName":"2940314","preferredDefinition":"Other NCCN approved regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-77B4-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73A203BA-77CD-3B75-E040-BB89AD435A96","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","deletedIndicator":"No"},{"value":"Taxotere, Doxoburicin and Cyclophosphamide for six cycles","valueDescription":"Taxotere, Doxoburicin and Cyclophosphamide for six cycles","ValueMeaning":{"publicId":"2940315","version":"1","preferredName":"Taxotere, Doxoburicin and Cyclophosphamide for six cycles","longName":"2940315","preferredDefinition":"Taxotere, Doxoburicin and Cyclophosphamide for six cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-77D7-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73A203BA-77F0-3B75-E040-BB89AD435A96","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","deletedIndicator":"No"},{"value":"Doxorubicin and Cyclophosphamide every 2 weeks for four Cycles followed by Paclitaxel every 2 weeks for four cycles","valueDescription":"Doxorubicin and Cyclophosphamide every 2 weeks for four Cycles followed by Paclitaxel every 2 weeks for four cycles","ValueMeaning":{"publicId":"2940316","version":"1","preferredName":"Doxorubicin and Cyclophosphamide every 2 weeks for four Cycles followed by Paclitaxel every 2 weeks for four cycles","longName":"2940316","preferredDefinition":"Doxorubicin and Cyclophosphamide every 2 weeks for four Cycles followed by Paclitaxel every 2 weeks for four cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-77FA-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73A203BA-7813-3B75-E040-BB89AD435A96","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","deletedIndicator":"No"},{"value":"Doxorubicin and Cyclophosphamide every 3 weeks for four Cycles followed by Paclitaxel every week for twelve weeks","valueDescription":"Doxorubicin and Cyclophosphamide every 3 weeks for four Cycles followed by Paclitaxel every week for twelve weeks","ValueMeaning":{"publicId":"2940317","version":"1","preferredName":"Doxorubicin and Cyclophosphamide every 3 weeks for four Cycles followed by Paclitaxel every week for twelve weeks","longName":"2940317","preferredDefinition":"Doxorubicin and Cyclophosphamide every 3 weeks for four Cycles followed by Paclitaxel every week for twelve weeks","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-781D-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73A203BA-7836-3B75-E040-BB89AD435A96","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","deletedIndicator":"No"},{"value":"Taxotere and Cyclophosphamide every 3 weeks for four Cycles","valueDescription":"Taxotere and Cyclophosphamide every 3 weeks for four Cycles","ValueMeaning":{"publicId":"2940318","version":"1","preferredName":"Taxotere and Cyclophosphamide every 3 weeks for four Cycles","longName":"2940318","preferredDefinition":"Taxotere and Cyclophosphamide every 3 weeks for four Cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-7840-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73A203BA-7859-3B75-E040-BB89AD435A96","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","deletedIndicator":"No"},{"value":"Doxorubicin and Cyclophosphamide every 3 weeks for four cycles","valueDescription":"Doxorubicin and Cyclophosphamide every 3 weeks for four cycles","ValueMeaning":{"publicId":"2940319","version":"1","preferredName":"Doxorubicin and Cyclophosphamide every 3 weeks for four cycles","longName":"2940319","preferredDefinition":"Doxorubicin and Cyclophosphamide every 3 weeks for four cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-7863-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73A203BA-787C-3B75-E040-BB89AD435A96","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"ONEDATA","dateModified":"2009-09-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73A203BA-77A0-3B75-E040-BB89AD435A96","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"NCCN Preferred Regimen receiv","type":"Preferred Question Text","description":"NCCN Preferred Regimen received","url":null,"context":"CTEP"}],"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"73A2950A-3C0E-4C55-E040-BB89AD4301CA","latestVersionIndicator":"Yes","beginDate":"2009-09-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-15","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}